The information you provided only concerns the correction of errors in the 2025 Lancet publication of the VICTOR study. These are technical corrections: Figure 1 should have included 3052 patients in the placebo group, Figure 3 corrected the alignment of elements, and added support from the Italian Ministry of Health to Prof. Giuseppe MC Rosano. If you would like a summary of the VICTOR study itself, it looked at the effectiveness of vericiguat in patients with chronic heart failure and reduced ejection fraction. The study did not show a statistically significant improvement in the primary endpoint (cardiovascular death or hospitalization for heart failure), but vericiguat reduced cardiovascular death by 17% compared with placebo (9.6% vs. 11.3%). Approximately 6,000 patients participated in the study and follow-up lasted an average of 18.5 months.